← All trials
NCT05920343
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2026
- First posted
- Jun 27, 2023
- Last posted
- Nov 1, 2023
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OttawaLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkCollaborator
- University of OttawaOverall official - principal investigator
- University of OttawaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.